iPSC-Derived Blood Stem Cells Achieve Long-Term Engraftment in Mice

One of regenerative medicine's most elusive goals has been producing genuine hematopoietic stem cells (HSCs) from human pluripotent stem cells. HSCs from patient-derived iPSCs could eliminate donor-host mismatch and graft-versus-host disease, treat genetic blood disorders via gene-edited cells, and model hematopoietic disease. Previous protocols generated progenitors with limited or short-term engraftment, failing to recapitulate the robust long-term multilineage repopulation that defines a true HSC.

The researchers developed a stepwise differentiation protocol mimicking intraembryonic hematopoiesis. Human iPSCs were differentiated as embryoid bodies in a chemically defined medium supplemented with retinyl acetate (a retinoic acid precursor), driving cells through HOXA-patterned posterior mesoderm—the developmental trajectory associated with definitive, adult-type HSCs. Subsequent exposure to BMP4 and VEGF specified hemogenic endothelium, the transitional cell type from which HSCs emerge during embryonic development. Critically, withdrawal of VEGF then facilitated efficient endothelial-to-hematopoietic transition (EHT), releasing CD34+ hematopoietic cells into the culture supernatant. These cells were collected and cryopreserved for downstream transplantation.

Transplantation experiments used immune-deficient NOD,B6.Prkdc-scid Il2rg-tm1Wjl/SzJ Kit-W41/W41 mice, a highly permissive host strain. Intravenous injection of two million thawed CD34+ cells derived from four independent iPSC lines produced long-term (>16 week) multilineage bone marrow engraftment in 25–50% of recipient mice. Engrafted human cells reconstituted myeloid, erythroid, B-lymphoid, and T-lymphoid lineages, fulfilling the gold-standard functional definition of HSC activity. Engraftment levels were comparable to those achieved with human umbilical cord blood transplantation, a clinically validated HSC source. Secondary transplantation experiments confirmed true self-renewal capacity of the iHSCs.

Transcriptomic and epigenomic analyses showed that iHSCs closely resembled fetal liver HSCs and expressed the HOXA gene signature characteristic of definitive, engrafting HSCs, distinguishing them from yolk-sac-derived progenitors. The retinyl acetate supplementation was identified as a key driver of HOXA patterning, pushing differentiation toward the intraembryonic aorta-gonad-mesonephros (AGM)-like trajectory rather than the extraembryonic yolk sac route taken by earlier protocols.

These findings represent a meaningful translational advance. The protocol is defined, reproducible across multiple iPSC lines, and yields cryopreservable cells—all prerequisites for clinical manufacturing. However, the current engraftment frequencies and absolute HSC numbers may still need optimization for clinical application, and long-term safety, including oncogenic risk from the reprogramming and differentiation process, requires careful evaluation before human trials.